Cancer of Colon Clinical Trial
Official title:
Multicenter RCT on Effects of Preoperative Immunonutrition on Patients Undergoing Elective Colorectal Surgery for Neoplasm: Changes in Adipose Tissue Inflammation and Correlation With Surgical Outcome for Future ERAS Guidelines.
Verified date | June 2023 |
Source | University of Roma La Sapienza |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Enhanced Recovery After Surgery (ERAS) protocols were developed to standardize perioperative practice in colon surgery to reduce morbidity, improve recovery, and shorten length of stay (LOS). Better protocol adherence translates into fewer readmissions and complications, and better 5-year survival. Preoperative elements, especially nutrition and immunonutrition, are topics that need further development to become the standard of care. It has been widely reported that the prevalence of malnutrition reaches 40% in cancer patients at the time of diagnosis. Impaired nutritional status at the time of surgery and cancer-induced inflammation, along with postoperative inflammatory responses to major surgery, increase the risk of postoperative complications, along with a decrease in perceived quality of life. Immunonutrition can modulate inflammation and reduce postoperative infections and shorten length of stay by counteracting the immune response induced by cancer. Adipose tissue has been shown to be a relevant source of inflammatory mediators, which may play a role in the promotion of tumor cachexia. The present study is a multicenter randomized control study (RCT) designed to evaluate the effect of preoperative immunonutrition in patients with colorectal cancer eligible for elective minimally invasive procedures, evaluating in particular surgical site infection and length of hospital stay. A biopsy of subcutaneous adipose tissue and visceral adipose tissue will also be performed, in order to evaluate the differences between inflammatory infiltrate, degree of fibrosis and cross-sectional area of adipocytes compared to controls.
Status | Not yet recruiting |
Enrollment | 216 |
Est. completion date | October 31, 2025 |
Est. primary completion date | March 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 85 Years |
Eligibility | Inclusion Criteria: - primary colorectal neoplasms eligible for elective surgery, undergoing minivasive resections. - 20 to 85 years old, with no difficulties in oral intake - BMI ranging from 18 to 40. Exclusion Criteria: - emergency surgery, - converted procedures, - major intraoperative complications, - concomitant chronic disease such as chronic renal failure, rheumatic and hematological disease, chronic inflammatory bowel diseases, - synchronous cancer, - previous bowel resections or bariatric surgery, - presence of preoperative stoma. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Roma La Sapienza |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Surgical site infection (SSI) | Number of participants developing surgical site infections (SSI), defined as wound/parietal infection or intra-abdominal abscess without any anastomotic leak. | 30 days after the surgical procedure | |
Secondary | Anastomotic leakage (AL) | Number of participants developing anastomotic leakage (AL), defined as the evidence of leakage at the ileocolic or colo-colic or colo-rectal anastomosis, diagnosed with imaging modalities or with reoperation | 30 days after the surgical procedure | |
Secondary | Length of stay (LOS) | Mean and Median Length of stay (LOS), defined as the mean and median number of days of hospitalization from the day of the surgical procedure to the day of patients' discharge | at patients' discharge | |
Secondary | Inflammatory infiltration in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) | Number of inflammatory cells in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.). | at the time of tissue analysis, usually 1 month after surgery | |
Secondary | grade of fibrosis in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) | Number of fibroblasts in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.). | at the time of tissue analysis, usually 1 month after surgery | |
Secondary | Adipocytes cross sectional area (CSA) in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) | Adipocytes cross sectional area (CSA) in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.). | at the time of tissue analysis, usually 1 month after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06454071 -
Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients
|
Phase 2 | |
Recruiting |
NCT05982184 -
Effect of Music Prehabilitation on Preoperative Anxiety Before Surgery
|
N/A | |
Completed |
NCT04160650 -
Educational Nursing Intervention Among Patients With Colorectal Cancer During Chemotherapy
|
N/A | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Completed |
NCT04716010 -
Developing and Evaluating Product Messaging
|
N/A | |
Terminated |
NCT03524820 -
Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02458664 -
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
|
N/A | |
Completed |
NCT03246438 -
Choice Architecture and Colorectal Cancer Screening Outreach
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Not yet recruiting |
NCT03910283 -
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
|
N/A | |
Completed |
NCT03928678 -
Implementation of Enhanced Recovery After Surgery Program (ERAS) in Colorectal Cancer Surgery, a Randomized Controlled Trial
|
N/A | |
Completed |
NCT03546569 -
Tumor Cells, Tumor DNA and Immunological Response in Colonic Stent Placement
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Not yet recruiting |
NCT06035731 -
Evaluation of the Medical Service by Socio-aesthetics in Oncology
|
N/A | |
Completed |
NCT04971304 -
Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
|
||
Completed |
NCT05030090 -
Integrative Nutrition Care Plan for the Patient With Liver and Colorectal Cancer
|
N/A | |
Not yet recruiting |
NCT04773626 -
Tumor Deposits in Cancer Colon
|
||
Recruiting |
NCT05887531 -
Abdominopelvic Cancer Prehabilitation
|
N/A | |
Withdrawn |
NCT04274790 -
Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer
|
||
Completed |
NCT03416777 -
Meat-based Versus Pesco-vegetarian Diet and Colorectal Cancer
|
N/A |